Progress of programmed death-1/programmed death-ligand 1 inhibitors in treatment of triple-negative breast cancer / 肿瘤研究与临床
Cancer Research and Clinic
;
(6): 957-960, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-934617
ABSTRACT
Breast cancer is the malignant tumor with the highest incidence among women in the worldwide. The triple-negative breast cancer (TNBC) has the strongest immunogenicity. Because of the lack of clear molecular targets, TNBC is a subtype of breast cancer with more difficulties in the treatment and poorer prognosis compared to other breast cancer subtypes. Blocking the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling pathway has been a hot spot of research and treatment of tumors. PD-1/PD-L1 inhibitors provide new treatment options for TNBC. This article reviews the research progress of PD-1/PD-L1 inhibitors alone or in combination with other drugs in treatment of TNBC, intending to provide the theoretical basis for basic or clinical studies.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Cancer Research and Clinic
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS